Bullfrog AI Holdings CEO Issued Letter To Shareholders, Highlights Pre-clinical Animal Study For Liver Disease And Obesity Drug Candidate, BF-114, Targeting Lucrative Market For Obesity Drugs, Which May Exceed $77B By 2030
Benzinga Newsdesk - Dec 29, 2023, 8:05AM